Combined JAK2 and HSP90 inhibition produces synergistic anti-tumour activity across preclinical glioblastoma models
Year: 2026
Type: preprint
Abstract: Background: Glioblastoma (GBM) remains difficult to treat because of tumour heterogeneity and the limited activity of single-target therapies. Our previous phenotypic drug screen identified JAK2/STAT3 signalling and HSP90-dependent protein homeostasis as pharmacological vulnerabilities. We investigated whether combined JAK2 and HSP90 inhibition could produce broader anti-tumour activity across GBM models. Methods: Multiple JAK2 and HSP90 inhibitors were tested alone and in combination across 2- and 3-dimensional patient-derived GBM stem cell models. Drug interactions were quantified using the zero-interaction potency (ZIP) synergy model. Mechanistic studies included RNA sequencing, flow cytometry, western blotting, immunofluorescence and FUCCI live-cell imaging. Activity was also assessed in cerebral organoid GBM co-cultures, non-malignant human neural and glial cells and orthotopic GBM xenografts. Results: Combined JAK2 and HSP90 inhibition produced synergistic interactions in 12 of the 13 GBM cell lines tested, using multiple structurally distinct inhibitor pairs. Gandotinib and NMS-E973 were selected for further mechanistic studies, where the combination reduced spheroid growth and increased caspase-3 activation and PARP cleavage. Combination treatment was associated with G2/M accumulation, altered mitotic regulation, abnormal chromosome and spindle organisation, and increased gamma-H2AX signalling. Anti-tumour combination activity was maintained in cerebral organoid co-cultures, where tumour burden was reduced as assessed by imaging, histological and luciferase-based measurements, while the drug combination had relatively limited effects on non-malignant human neural and glial cell types tested over the same concentration range. In vivo, combined Pacritinib and NMS-E973 treatment significantly reduced tumour burden in orthotopic G7 xenografts compared with vehicle or either single agent. Conclusions: JAK2/HSP90 co-inhibition produces reproducible anti-tumour activity across heterogeneous GBM models and disrupts cell-cycle and mitotic progression. These findings support further evaluation of this combination strategy in GBM.
Authors: Muhammad Furqan, Richard J.R. Elliott, Alexander E.P. Loftus, Wai Kit Chan, Roza Masalmeh, Martin Lee, Morwenna T Muir, Fraser Laing, John C Dawson, Peter W.K. Nagle, Roderick N Carter, Bhuvaneish Thangaraj Selvaraj, Paul Baxter, Alison F Munro, Camilla Drake, Vanessa Smer-Barreto, Gillian M Morrison, Steven M Pollard, John O Mason, Valerie G Brunton, Margaret C Frame, Neil O Carragher
Institution: University of Edinburgh
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236699279
